FDA Logo--links to FDA home page
U.S. Food and Drug Administration
HHS Log--links to Department of Health and Human Services website
FDA Home Page | About MedWatch | Contact MedWatch | MedWatch Partners
 MedWatch logoThe FDA Safety Information and Adverse Event Reporting Program


 
 

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- April 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.

Summary View

 

 

Brand (Generic) Name

Sections Modified

Summary of Changes to Contraindications and Warnings

Aldurazyme (laronidase) Solution for Intravenous Infusion Only

Prescribing Information

 

 

BOXED WARNING (new)

  • Risk of Anaphylaxis

WARNINGS

  • Anaphylaxis and Allergic Reactions (see BOXED WARNING)

ADVERSE REACTIONS

  • Initial Paragraph
  • In clinical studies, the most common adverse reactions requiring intervention...
  • In postmarketing experience with Aldurazyme...
  • Immunogenicity

BOXED WARNING

WARNING: Risk of Anaphylaxis

Life-threatening anaphylactic reactions have been observed in some patients during Aldurazyme infusions. Therefore, appropriate medical support should be readily available when Aldurazyme is administered. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions, and require additional monitoring.

WARNINGS: Anaphylaxis and Allergic Reactions (see BOXED WARNING)

See prescribing information for revised text.

Emtriva (emtricitabine) Capsules and Oral Solution

Prescribing Information

Patient Package Insert

BOXED WARNING

WARNINGS

  • Patients Co-infected with HIV and Hepatitis B Virus

PATIENT PACKAGE INSERT

  • What is the most important information I should know about Emtriva?
    • If you are also infected with the Hepatitis B Virus (HBV)...
  • What are the possible side effects of Emtriva?
    • "flare-ups" of Hepatitis B Virus infection...

BOXED WARNING

...Emtriva is not approved for the treatment of Chronic Hepatitis B Virus (HBV) Infection...

WARNINGS: Patients Co-infected with HIV and Hepatitis B Virus

...Emtriva is not approved for the treatment of chronic HBV infection...

...In some patients infected with HBV and treated with Emtriva, the exacerbations of hepatitis B were associated with liver decompensation and liver failure...

clear

clear

clear

Lotronex (alosetron hydrochloride) Tablets

Prescribing Information (in new labeling format)

Medication Guide

 

 

BOXED WARNING

  • WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS

WARNINGS AND PRECAUTIONS

  • Serious Complications of Constipation
  • Ischemic Colitis
  • Prescribing Program for Lotronex

ADVERSE REACTIONS

  • Clinical Trials Experience
    • Initial Paragraph
    • Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome
      • Table 2
      • Constipation

DRUG INTERACTIONS

  • Initial Paragraph

USE IN SPECIFIC POPULATIONS

  • Pediatric Use
  • Geriatric Use
  • Hepatic Impairment
  • Renal Impairment

PATIENT COUNSELING INFORMATION

  • Physician and Patient Responsibilities

MEDICATION GUIDE

  • There is a special prescribing program for Lotronex.
  • What is Lotronex?
  • Who should not take Lotronex?
  • What should I talk about with my doctor before taking Lotronex?
  • What are the possible side effects of Lotronex?
  • How should I store Lotronex?
  • General information about the safe and effective use of Lotronex.

BOXED WARNING

WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS

...Only physicians who have enrolled in the Prometheus Prescribing Program for Lotronex based on their understanding of the benefits and risks, should prescribe Lotronex...

WARNINGS AND PRECAUTIONS

Serious Complications of Constipation

...Complications of constipation have been reported with use of 1 mg twice a daily and with lower doses. A dose response relationship has not been established for serious complications of constipation...

Ischemic Colitis

Some patients have experienced ischemic colitis without warning...

...Ischemic colitis has been reported with use of 1 mg twice daily and with lower doses. A dose-response relationship has not been established. Ischemic colitis was reported in one patient receiving placebo.

Prescribing Program for Lotronex

(See highlighted text for labeling revisions.)

Back to Summary Page | Back to Top

Brand (Generic) Name

Sections Modified

Summary of Changes to Contraindications and Warnings

Advair Diskus (fluticasone propionate and salmeterol inhalation powder)

Prescribing Information (in new labeling format)

Medication Guide

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

  • Deterioration of Disease and Acute Episodes
  • Pneumonia
  • Drug Interactions With Strong Cytochrome P450 3A4 Inhibitors

ADVERSE REACTIONS

  • Clinical Trials Experience in Asthma
    • Adult and Adolescent Patients 12 Years of Age and Older
    • Table 2
  • Clinical Trials Experience in Chronic Obstructive Pulmonary Disease
    • Short-Term (6 Months to 1 Year) Trials
    • Table 3
  • Postmarketing Experience
    • Musculoskeletal, Connective Tissue, and Bone Disorders
      • Arthralgia
    • Psychiatric Disorders
      • Behavioral changes, including hyperactivity and irritability, have been reported very rarely and primarily in children.

DRUG INTERACTIONS

  • Inhibitors of Cytochrome P450 3A4
    • Initial Paragraph
    • Ketoconazole: Salmeterol
  • Beta-Adrenergic Receptor Blocking Agents

USE IN SPECIFIC POPULATIONS

  • Pregnancy
  • Pediatric Use
  • Geriatric Use
  • Hepatic Impairment
  • Renal Impairment

PATIENT COUNSELING INFORMATION

  • Pneumonia

MEDICATION GUIDE

  • What is Advair Diskus
    • Chronic Obstructive Pulmonary Disease
  • Who should not use Advair Diskus?
  • What should I tell my healthcare provider before using Advair Diskus?
    • ...are allergic to any of the ingredients in Advair Diskus...
  • How do I use Advair Diskus?
  • What are the possible side effects with Advair Diskus?
  • The most common side effects with Advair Diskus include...

CONTRAINDICATIONS

Severe hypersensitivity to milk proteins...

WARNINGS AND PRECAUTIONS

Deterioration of Disease and Acute Episodes

Advair Diskus should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD. Advair Diskus has not been studied in patients with acutely deteriorating asthma or COPD...

Pneumonia

Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap.

Lower respiratory tract infections, including pneumonia, have been reported in patients with COPD following the inhaled administration of corticosteroids, including fluticasone propionate and Advair Diskus. In 2 replicate 12-month studies of 1,579 patients with COPD, there was a higher incidence of pneumonia reported in patients receiving Advair Diskus 250/50 (7%) than in those receiving salmeterol 50 mcg (3%). The incidence of pneumonia in the patients treated with Advair Diskus was higher in patients over 65 years of age (9%) compared with the incidence in patients less than 65 years of age (4%)...

Drug Interactions With Strong Cytochrome P450 3A4 Inhibitors

The use of strong CYP 3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with Advair Diskus is not recommended because increased systemic corticosteroid and increased cardiovascular adverse effects may occur...

clear pixel

clear pixel

clear pixel

Amitiza (lubiprostone) Capsules

Prescribing Information (in new labeling format)

 

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

  • Dyspnea

ADVERSE REACTIONS

  • Clinical Studies Experience
    • Chronic Idiopathic Constipation
      • Table 1
      • Nausea
      • Diarrhea
      • Less common adverse reactions
    • Irritable Bowel Syndrome with Constipation
      • Table 2
      • Less common adverse reactions
  • Postmarketing Experience

USE IN SPECIFIC POPULATIONS

  • Pregnancy
  • Geriatric Use
    • Irritable Bowel Syndrome with Constipation

NONCLINICAL TOXICITY

  • Carcinogenesis, Mutagenesis, Impairment of Fertility
    • Carcinogenesis
    • Impairment of Fertility

PATIENT COUNSELING INFORMATION

  • Dosing Instructions
  • Irritable Bowel Syndrome with Constipation

CONTRAINDICATIONS

Amitiza is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS:  Dyspnea

In clinical trials conducted to study Amitiza in treatment of chronic idiopathic constipation and IBS-C there were reports of dyspnea. This was reported at 2.5% of the treated chronic idiopathic constipation population and at 0.4% in the treated IBS-C population. Although not classified as serious adverse events, some patients discontinued treatment on study because of this event. There have been postmarketing reports of dyspnea when using Amitiza 24 mcg...

 

...These events have usually been described as a sensation of chest tightness and difficulty taking in a breath, and generally have an acute onset within 30-60 minutes after taking the first dose. They generally resolve within a few hours after taking the dose, but recurrence has been frequently reported with subsequent doses.

clear pixel

clear pixel

clear pixel

Crixivan (indinavir sulfate) Capsules

Prescribing Information

Patient Package Insert

CONTRAINDICATIONS

  • Table 7
    • Oral Midazolam

WARNINGS

  • Drug Interactions
    • Rosuvastatin (added)
    • ...Dosage reduction for midazolam...

PRECAUTIONS

  • Drug Interactions
    • Table 8: Drugs That Should Not Be Coadministered with Crixivan
      • Sedative/hypnotics
        • Oral Midazolam
    • Table 9: Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction
      • HMG-CoA Reductase Inhibitors
        • Rosuvastatin
    • Midazolam (parenteral administration)

PATIENT PACKAGE INSERT

  • Can Crixivan be taken with other medications?
    • Medicines you should not take with Crixivan
      • Oral Versed (midazolam)
    • In addition, you should not take Crixivan with the following:
      • Crestor (rosuvastatin)
    • Medicines you can take with Crixivan
      • Intravenous Versed (midazolam) - If you take Crixivan with Intravenous Versed, your doctor may adjust the does of Versed.

CONTRAINDICATIONS

Table 7: Drug Interactions With Crixivan: Contraindicated Drugs

Drug Class: Sedative/hypnotics

Oral midazolam (added as contraindicated drug)

(See highlighted text for labeling revisions.)

WARNINGS

Drug Interactions

Caution should be exercised if HIV protease inhibitors, including Crixivan, are used concurrently with other HMG-CoA reductase inhibitors that are also metabolized by the CYP3A4 pathway (e.g., atorvastatin or rosuvastatin).

...If Crixivan with or without ritonavir is co-administered with parenteral midazolam, it should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.

clear pixel

clear pixel

clear pixel

Tigan (trimethobenzamide hydrochloride) Injectable for Intramuscular Use Only

Prescribing Information

CONTRAINDICATIONS

PRECAUTIONS

  • General
    • Adjustment of Dose in Renal Failure
  • Geriatric Use

CONTRAINDICATIONS

The injectable form of Tigan is contraindicated in pediatric patients and in patients with known hypersensitivity to trimethobenzamide.

Back to Summary Page | Back to Top

Brand (Generic) Name

Sections Modified

Summary of Changes to Contraindications and Warnings

Actonel (risedronate sodium) Tablets

Prescribing Information (in new labeling format)

Patient Package Insert

 

WARNINGS AND PRECAUTIONS

  • Upper Gastrointestinal Adverse Reactions
  • Musculoskeletal Pain

ADVERSE REACTIONS

  • Clinical Studies Experience
    • Treatment of Postmenopausal Osteoporosis
    • Daily Dosing
      • Table 1
      • Gastrointestinal Adverse Events
      • Musculoskeletal Adverse Events
      • Laboratory Test Findings
    • Once-a-week Dosing
      • Gastrointestinal Adverse Events
    • Monthly Dosing
      • Two Consecutive Days per Month
      • Acute Phase Reactions
      • Gastrointestinal Adverse Events
      • Ocular Adverse Events
      • Laboratory Test Findings
    • Once a Month
      • Acute Phase Reactions
      • Gastrointestinal Adverse Events
      • Ocular Adverse Events
      • Laboratory Test Findings
    • Prevention of Postmenopausal Osteoporosis
      • Daily Dosing
      • Once-a-week Dosing
    • Treatment and Prevention of Glucocorticoid-induced Osteoporosis
    • Treatment of Paget's Disease
      • Table 2
  • Postmarketing Experience
    • Gastrointestinal Adverse Events

PATIENT COUNSELING INFORMATION

  • If the dose of Actonel 150 mg once a month is missed...

PATIENT PACKAGE INSERT

  • How should I take Actonel?
  • What is my Actonel schedule?
  • What should I avoid while taking Actonel?
  • What are the possible side effects of Actonel?
  • Other possible side effects may include...
  • Call you doctor for medical advice about side effects.
  • How should I store Actonel?

WARNINGS AND PRECAUTIONS

Upper Gastrointestinal Adverse Reactions

...Patients should discontinue use if new or worsening symptoms occur...

Musculoskeletal Pain

...Consider discontinuing use if severe symptoms develop.

 

Augmentin (amoxicillin/clavulanate potassium) Tablets

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

  PRECAUTIONS

  • Information for Patients
    • …Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Augmentin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

 

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

 

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Augmentin ES-600 (amoxicillin/clavulanate potassium) Powder for Oral Suspension

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

  PRECAUTIONS

  • Information for Patients
    • …Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Augmentin ES-600, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

 

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

 

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Augmentin XR (amoxicillin/clavulanate potassium) Extended Release Tablets

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

  PRECAUTIONS

  • Information for Patients
    • …Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Augmentin XR, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

 

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

 

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Declomycin (demeclocycline hydrochloride) Tablets

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

 

PRECAUTIONS

  • Information for Patients
    • …Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Declomycin (demeclocycline hydrochloride), and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

clear

clear

clear

Evamist (estradiol transdermal spray)

Prescribing Information (in new labeling format)

 

WARNINGS AND PRECAUTIONS

  • Malignant Neoplasms
    • Breast Cancer
  • Dementia

USE IN SPECIFIC POPULATIONS

  • Geriatric Use

 

WARNINGS AND PRECAUTIONS

Malignant Neoplasms: Breast Cancer

The most important randomized clinical trial providing information about this issue in estrogen alone users is the Women’s Health Initiative (WHI) substudy of daily conjugated estrogens (CE 0.625 mg)...

The most important randomized clinical trial providing information about this issue in estrogen plus progestin users is the Women’s Health Initiative (WHI) substudy of daily CE 0.625 mg plus medroxyprogesterone acetate (MPA 2.5 mg)...

Observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment...

Dementia

...Since both substudies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women...

clear

clear

clear

Levaquin (levofloxacin) Tablets and Oral Solution

Levaquin (levofloxacin) Injection, for Intravenous Use

Levaquin (levofloxacin in 5% dextrose) Injection, for Intravenous Use

Prescribing Information (in new labeling format)

Patient Package Insert


WARNINGS AND PRECAUTIONS

  • Hepatotoxicity

ADVERSE REACTIONS

  • Serious and Otherwise Important Adverse Reactions
    • Hepatotoxicity...

USE IN SPECIFIC POPULATIONS

  • Geriatric Use
    • Severe, and sometimes fatal, cases of hepatotoxicity have been reported postmarketing in association with Levaquin...

PATIENT COUNSELING INFORMATION

  • Serious and Potentially Serious
    Adverse Reactions
    • Hepatotoxicity

PATIENT PACKAGE INSERT

  • What are possible side effects of Levaquin?
    • Hepatotoxicity (liver damage)...

WARNINGS AND PRECAUTIONS

Postmarketing reports of severe hepatotoxicity (including acute hepatitis and fatal events) have been received for patients treated with Levaquin. No evidence of serious drug-associated hepatotoxicity was detected in clinical trials of over 7,000 patients. Severe hepatotoxicity generally occurred within 14 days of initiation of therapy and most cases occurred within 6 days. Most cases of severe hepatotoxicity were not associated with hypersensitivity [see Warnings and Precautions (5.2)]. The majority of fatal hepatotoxicity reports occurred in patients, 65 years of age or older and most were not associated with hypersensitivity. Levaquin should be discontinued immediately if the patient develops signs and symptoms of hepatitis...

clear

clear

clear

Luvox (fluvoxamine maleate) Tablets

Prescribing Information (in new labeling format)

 

 

 

WARNINGS AND PRECAUTIONS

  • Other Potentially Important Drug Interactions
    • Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.)
  • Abnormal Bleeding

PATIENT COUNSELING INFORMATION

  • Concomitant Medication

WARNINGS AND PRECAUTIONS

Other Potentially Important Drug Interactions: Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.)

Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Thus, patients should be cautioned about the use of such drugs concurrently with fluvoxamine...

Abnormal Bleeding

SSRI’s and SNRI’s, including Luvox Tablets, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRI’s and SNRI’s have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages.

Patients should be cautioned about the risk of bleeding associated with the concomitant use of Luvox Tablets and NSAID’s, aspirin, or other drugs that affect coagulation [see section 5.7].

clear

clear

clear

Nafcillin Injection, USP
in PL 2040 Plastic Container For Intravenous Use Only Galaxy Container

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

 

PRECAUTIONS

  • Information for Patients
    • …Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Nafcillin Injection, USP, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

clear

clear

clear

Neulasta (pegfilgrastim)

Prescribing Information

Patient Package Insert

 

WARNINGS

  • Allergic Reactions

ADVERSE REACTIONS

  • Postmarketing Experience (new subsection)

PATIENT PACKAGE INSERT

  • What is Neulasta used for?
  • What are possible serious side effects of Neulasta?
    • Serious Allergic Reactions
      • Hives

WARNINGS

Allergic Reactions

Allergic reactions to Neulasta, manifesting as anaphylaxis, angioedema, or urticaria have been reported in postmarketing experience...

clear

clear

clear

Orencia (abatacept)
Lyophilized Powder for Intravenous Infusion

Prescribing Information (in new labeling format)

Patient Package Insert

WARNINGS AND PRECAUTIONS

  • Hypersensitivity
  • Infections
  • Immunizations

ADVERSE REACTIONS

  • Clinical Studies Experience in Juvenile Idiopathic Arthritis
    • Immunogenicity
  • Postmarketing Experience

DRUG INTERACTIONS

  • Other Biologic RA Therapy

USE IN SPECIFIC POPULATIONS

  • Pregnancy
    • Pregnancy Registry
  • Pediatric Use

NONCLINICAL TOXICITY

  • Carcinogenesis, Mutagenesis, Impairment of Fertility

PATIENT COUNSELING INFORMATION

  • Concomitant Use With Biologic Medications for RA
    • Hypersensitivity
    • Infections
    • Immunizations
    • Pregnancy and Nursing Mothers
    • Blood Glucose Testing

PATIENT PACKAGE INSERT

  • What is Orencia?
  • What should I tell my doctor before treatment with Orencia?
    • Tell your doctor about all the medicines you take...
  • What are the possible side effects of Orencia?
  • Common side effects of Orencia in both adults and children...
  • In children, other side effects may include...
  • General information about Orencia
  • What are the ingredients in Orencia?

WARNINGS AND PRECAUTIONS

Hypersensitivity

...Of the 190 patients with juvenile idiopathic arthritis treated with Orencia in clinical trials, there was one case of a hypersensitivity reaction (0.5%)...

Infections

...Anti-rheumatic therapies have been associated with hepatitis B reactivation. Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with Orencia. In clinical studies with Orencia, patients who screened positive for hepatitis were excluded from study.

Immunizations

...It is recommended that patients with juvenile idiopathic arthritis be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating Orencia therapy.

clear

clear

clear

Oxacillin (oxacillin) Injection, Solution in Plastic Container
For Intravenous Use Only Galaxy Container (PL 2040)

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

  PRECAUTIONS

  • Information for Patients
    • …Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Oxacillin Injection, USP, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

clear

clear

clear

Pipracil (piperacillin for injection) for Intravenous and Intramuscular Use

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

PRECAUTIONS

  • Information for Patients
    • ...Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Pipracil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

clear

clear

clear

Prevacid (lansoprazole) Delayed-Release Capsules

Prevacid (lansoprazole) Delayed-Release Oral Suspension

Prevacid SoluTab (lansoprazole) Delayed-Release Orally Disintegrating Tablets

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

PRECAUTIONS

  • Drug Interactions
    • Atazanavir
    • ...It is theoretically possible that Prevacid may also interfere...

ADVERSE REACTIONS

  • Clinical
    • Another study for the same indication, where patients took either a COX-2 inhibitor or lansoprazole and naproxen...
  • Laboratory Values
    • Blood Potassium Increased
    • Blood Urea Increased
    • Crystal Urine Present
    • Hemoglobin Decreased
    • Positive Fecal Occult Blood

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clarithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

clear

clear

clear

Timentin (ticarcillin disodium and clavulanate potassium) for Intravenous Administration

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

PRECAUTIONS

  • Information for Patients
    • ...Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Timentin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

clear

clear

clear

Timentin (ticarcillin disodium and clavulanate potassium) Injection

Galaxy (PL 2040) Plastic Container

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

PRECAUTIONS

  • Information for Patients
    • ...Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Timentin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

clear

clear

clear

Unasyn (ampicillin sodium/sulbactam sodium)

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

PRECAUTIONS

  • Information for Patients
    • ...Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Unasyn, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

clear

clear

clear

Vyvanse (lisdexamfetamine dimesylate) Capsules

Prescribing Information (in new labeling format)

 

WARNINGS AND PRECAUTIONS

  • Prescribing and Dispensing

ADVERSE REACTIONS

  • Clinical Studies Experience
    • Initial Section
    • Adverse Reactions Occurring at an Incidence of 2% or more Among Vyvanse Treated Patients in Clinical Trials
      • Adult
        • Table 2
        • Vital Signs
  • Adverse Reactions Associated with the Use of Amphetamine
    • Central Nervous System
      • Insomnia
    • Gastrointestinal
      • Other Gastrointestinal Disturbances
    • Allergic
      • Rashes

DRUG INTERACTIONS

  • Agents that Increase Blood Levels of Amphetamines
    • Urinary Alkalinizing Agents

USE IN SPECIFIC POPULATIONS

  • Pregnancy
    • Initial Paragraph
  • Labor and Delivery
  • Pediatric Use

PATIENT COUNSELING INFORMATION

  • Controlled Substance Status/Potential for Abuse, Misuse, and Dependence
  • Serious Cardiovascular Risks
  • Psychiatric Risks
  • Growth
  • Pregnancy
  • Nursing
  • Impairment in Ability to Operate Machinery or Vehicles

WARNINGS AND PRECAUTIONS

Prescribing and Dispensing

The least amount of amphetamine feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. Vyvanse should be used with caution in patients who use other sympathomimetic drugs.

clear

clear

clear

Zosyn (piperacillin and tazobactam injection) in Galaxy Containers (PL 2040 Plastic)

Prescribing Information

 

 

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

PRECAUTIONS

  • Information for Patients
    • ...Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Zosyn, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

clear

clear

clear

Zosyn (piperacillin and tazobactam for injection) Individual Vials

Prescribing Information

Zosyn (piperacillin and tazobactam for injection) Pharmacy Bulk Package

Prescribing Information

WARNINGS

  • Clostridium difficile associated diarrhea (CDAD)

PRECAUTIONS

  • Information for Patients
    • ...Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued...

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Zosyn, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Back to Summary Page | Back to Top

Brand (Generic) Name
Sections Modified

Cardiolite Kit for the Preparation of Technetium Tc99m Sestamibi for Injection

Prescribing Information (in new labeling format)

 

USE IN SPECIFIC PATIENTS

  • Pediatric Use

Cetrotide (cetrorelix acetate for injection)  

Prescribing Information

PRECAUTIONS

  • General
    • Cases of hypersensitivity reactions, including anaphylactoid reactions with the first dose, have been reported during postmarketing surveillance…

Dibenzyline (phenoxybenzamine hydrochloride capsules, USP)

Prescribing Information

 

PRECAUTIONS

  • Carcinogenesis and Mutagenesis
    • Case reports of carcinoma in humans after long-term treatment with phenoxybenzamine have been reported. Hence long-term use of phenoxybenzamine is not recommended. Carefully weigh the benefits and risks before prescribing this drug...

Fiorinal with Codeine (butalbital, aspirin, caffeine, and codeine phosphate) Capsules

Prescribing Information

PRECAUTIONS

  • Ultra-rapid Metabolizers of Codeine

 

Maxitrol (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension)

Prescribing Information

PRECAUTIONS

  • Geriatric Use (new subsection)

Pilopine HS (pilocarpine hydrochloride ophthalmic gel) 4%

Prescribing Information

PRECAUTIONS

  • Geriatric Use

Propranolol Hydrochloride Injection, USP

Prescribing Information

PRECAUTIONS

  • General
    • ...Withdrawal may lead to a return of elevated intraocular pressure.

clear

clear

Pulmicort Flexhaler (budesonide inhalation powder) For Oral Inhalation Only

Prescribing Information

Patient Package Insert

PRECAUTIONS

  • General
    • Initial Paragraph
      • Pulmicort Flexhaler contains small amounts of lactose...
  • Information for Patients

ADVERSE REACTIONS

  • Adverse Event Reports from Other Sources
    • Postmarketing Experience

PATIENT PACKAGE INSERT

  • Before Using Your Pulmicort Flexhaler
  • What are the ingredients in Pulmicort Flexhaler?

Synthroid (levothyroxine sodium tablets, USP)

Prescribing Information

PRECAUTIONS

  • Information for Patients
    • Agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine sodium tablets. Therefore, levothyroxine sodium tablets should not be administered within 4 hours of these agents.

Tenormin (atenolol) Tablets

Prescribing Information

PRECAUTIONS

  • Drug Interactions
    • Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects...
    • Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers...
    • Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate...

Back to Summary Page | Back to Top

Brand (Generic) Name
Sections Modified

Copegus (ribavirin, USP) Tablets

Prescribing Information

ADVERSE REACTIONS

  • Postmarketing Experience
    • Dehydration

Enablex (darifenacin) Extended-Release Tablets

Prescribing Information

 

ADVERSE REACTIONS

  • Postmarketing Experience (new subsection)

Flomax (tamsulosin hydrochloride) Capsules

Prescribing Information

ADVERSE REACTIONS

  • Postmarketing Experience
    • Respiratory Symptoms

clear

clear

Lexiva (fosamprenavir calcium) Tablets and Oral Suspension

Prescribing Information (in new labeling format)

Patient Package Insert

 

 

 

ADVERSE REACTIONS

  • Postmarketing Experience
    • Skin and Subcutaneous Tissue Disorders
      • Angioedema

PATIENT PACKAGE INSERT

  • What are the possible side effects of Lexiva?
    • ...Swelling of the face, lips, and tongue (angioedema) has also been reported. Tell your healthcare provider if you get a rash or develop facial swelling after starting Lexiva.

Navane (thiothixene) Capsules
Navane (thiothixene hydrochloride) Concentrate

Prescribing Information

ADVERSE REACTIONS

  • Extrapyramidal Symptoms
    • Dystonia, Class Effect (new subsection)

clear pixel

clear pixel

RotaTeq (rotavirus vaccine, live, oral, pentavalent) Oral Solution

Prescribing Information (in new labeling format)

Patient Package Insert

ADVERSE REACTIONS

  • Postmarketing Experience
    • Gastrointestinal Disorders
      • Intussusception (including death)

PATIENT COUNSELING INFORMATION

PATIENT PACKAGE INSERT

  • What other important information should I know?
    • ...Death due to intussusception has also occurred...

clear pixel

clear pixel

Singulair (montelukast sodium) Granule

Singulair (montelukast sodium) Tablet, Chewable

Singulair (montelukast sodium) Tablet, Film Coated

Prescribing Information

Patient Package Insert

See MedWatch Safety Alert posted 03/27/2008 for additional information on Singulair

 

ADVERSE REACTIONS

  • Postmarketing Experience
    • Psychiatric Disorders
      • Anxiousness
      • Suicidal thinking and behavior (including suicide)

PATIENT PACKAGE INSERT

  • Less common side effects that have happened with Singulair include:
    • Behavior and Mood related changes
      • Feeling anxious
      • Suicidal thoughts and actions (including suicide)...

clear pixel

clear pixel
Theophylline in 5% Dextrose Injections, USP

Prescribing Information

ADVERSE REACTIONS

  • ...Hypercalcemia has been reported in a patient with hyperthyroid disease at therapeutic theophylline concentrations.

clear pixel

clear pixel

Zerit (stavudine) Capsules

Zerit (stavudine) for Oral Solution

Prescribing Information

Patient Package Insert

 

ADVERSE REACTIONS

  • Observed During Clinical Practice
    • Metabolic Disorders
      • Diabetes Mellitus and Hyperglycemia

PATIENT PACKAGE INSERT

  • What are the possible side effects of Zerit?
    • Other Side Effects
      • ...high blood sugar (hyperglycemia or diabetes)...

Back to Summary Page | Back to Top

   
NuvaRing (etonogestrel/ethinyl estradiol vaginal ring)

Patient Package Insert

Prescribing Information

PATIENT PACKAGE INSERT

  • How do I insert NuvaRing?
  • How do I remove NuvaRing?
  • Call your healthcare provider right away if you get any of the symptoms listed below...

Back to Summary Page | Back to Top